Ciraparantag (PER977): Anticoagulant Reversal Agent

Ciraparantag (PER977) is an intravenously administered synthetic molecule designed by Perosphere as a reversal agent for oral direct Factor Xa inhibitor and low molecular weight heparin anticoagulants.  

Anticoagulants are widely used for the prevention and treatment of a variety of thromboembolic events. While oral direct Factor Xa inhibitors exhibit predictable anticoagulant action and improved side effect profiles, bleeding remains their major complication. Pharmacologic anticoagulation becomes a clinical problem when anticoagulated patients experience major bleeding, or require emergency surgery -- which is the clinical motivation for developing a reversal agent for these anticoagulants.

Ciraparantag is an intravenously administered synthetic small molecule, invented by Perosphere, aimed at reversing Daiichi Sankyo Co., Ltd.'s Savaysa™/Lixiana® (edoxaban), Johnson & Johnson's and Bayer HealthCare AG's Xarelto® (rivaroxaban) and Bristol-Myers Squibb Company's and Pfizer Inc.'s Eliquis® (apixaban) when medically indicated.

Currently in Phase 2 clinical trials, ciraparantag has demonstrated complete and sustained reversal of Daiichi Sankyo’s SavaysaTM/Lixiana® (edoxaban) and Sanofi’s Lovenox® (enoxaparin sodium sub-cutaneous injection) as measured by whole blood clotting time. No pro-coagulant signals have been observed, as measured by D-dimer, F1.2, TFPI, or whole blood clotting time in clinical trials. Non-clinical studies have demonstrated reversal of Daiichi Sankyo's SavaysaTM/Lixiana® (edoxaban), Boehringer Ingelheim's Pradaxa® (dabigatran etexilate), Johnson & Johnson and Bayer's Xarelto® (rivaroxaban), Bristol-Myers Squibb and Pfizer's Eliquis® (apixaban) and Sanofi’s Lovenox® (enoxaparin sodium injection).